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Sera obtained from two groups of adult volunteers infected with Norwalk virus (NV) and two groups of
patients involved in two natural outbreaks were tested for NV-reactive immunoglobulin M (IgM) by use of a
monoclonal antibody, recombinant-antigen-based IgM capture enzyme immunoassay (EIA). No NV-reactive
IgM was detected in the preinoculation sera of 15 volunteers, and 14 of 15 showed NV-reactive antibodies post-
infection with NV. All of the volunteers showed IgG seroconversion to NV. In the outbreak studies, all 9 persons
in one outbreak and 19 of 24 in another outbreak had NV-reactive IgM. In the first outbreak, only three of nine
seroconverted to NV, which was likely due to late collection of acute-phase sera. In the second outbreak, 21 of
24 showed IgG seroconversion to NV. Sequencing of viruses isolated from five stool samples selected from those
in the second outbreak showed that they were human calicivirus (HuCV) genogroup 1 viruses related, but not
identical, to NV. In the volunteer studies, NV-reactive IgM was first detected 8 days postinoculation. The time
of development of NV-reactive IgM antibodies in natural outbreaks was estimated to be similar to that found
in the volunteer studies. Sera from three Hawaii virus-infected volunteers, four Snow Mountain virus patients,
and 80 healthy individuals were negative for NV-reactive IgM, indicating test specificity for HuCV genogroup
I infections. This capture IgM EIA is suitable for diagnosis of NV and other HuCV genogroup I infections and
is especially useful when sera and fecal samples have not been collected early in the course of an outbreak.
Human caliciviruses (HuCVs) are a major cause of viral
gastroenteritis during adolescence and adulthood (3). Viruses
in both Norwalk virus (NV) genogroup I (GI) and Snow
Mountain virus (SMV) GII are currently circulating (1, 4, 6, 20,
21, 24, 29, 30, 32). Because HuCVs have not been isolated in
cell culture, diagnosis is done by PCR, enzyme-linked immu-
nosorbent assay (ELISA) antigen detection, electron micros-
copy, or serologic methods. In the past, immunoreagents for
detection were obtained from human volunteer sera (14, 18).
With the development of a recombinant NV (rNV) capsid
antigen (19, 22), NV antigen was made available for use in
antibody detection and preparation. Rabbit and guinea pig
polyclonal antibodies have been prepared against rNV (10,
22), and mouse monoclonal antibodies against NV for detec-
tion of NV in stools have been described (16, 17). Serologic
tests once dependent on antigen in stools of volunteers (2, 14)
now use rNV (10, 12, 13, 22, 27).
Immunoglobulin G (IgG)-based serologic methods for NV
require appropriately timed, paired, acute- and convalescent-
phase serum (9), whereas a single serum may be used for
IgM-based methods. In one volunteer study, 2 of 20 volunteers
had low prechallenge levels of IgM antibodies (5). Another
study used an antibody capture method in which all volunteer
and also natural outbreak sera were IgM negative up to 3 days
after the onset of illness. Seven of 66 were IgM positive within
1 week after symptoms occurred. The test detected 17 of 18
infections in volunteers but only 43 of 72 naturally occurring
NV infections from sera collected 2 to 5 weeks after the onset
of illness (7).
By use of rNV, one study detected 14 of 14 infected volun-
teers in a direct binding IgM assay after removal of IgG and
IgA (11). IgM was detected in some volunteers as early as 9
days after inoculation, but other volunteers were negative as
late as 11 days after inoculation. In another study (31), an IgM
antibody capture test detected IgM in 15 of 15 volunteers.
There are no reports of the use of rNV in an antigen capture
ELISA in both volunteer and natural infections or of the use
of NV monoclonal antibodies in an IgM assay. Whether IgM
may, at times, be present in prechallenge sera and the time
required for IgM to be detected after infection are still unclear;
thus, the diagnostic utility of IgM for NV infection has not
been established. The purpose of this study was to determine
the diagnostic efficacy of a recombinant antigen, monoclonal-
antibody-based ELISA for NV-reactive IgM. Our results serve
as a model for detection of infections with other HuCVs. NV
was used because it is the prototype HuCV.
MATERIALS AND METHODS
Serum samples. Two groups of human volunteers were studied. Both groups
consisted of individuals who became ill and either had fourfold increases in
titers of IgG antibody against rNV or shed the virus in stool. The first group
(group I) consisted of nine individuals (2) from whom sera were collected
preinoculation and then 5 days to 22 weeks postinoculation with the 8FIIa strain
of NV. One volunteer was challenged with 8FIIa NV on two occasions 4 years
apart. The second group (group II) of five volunteers was inoculated with 8FIIa
NV in 1995 (26a), and sera were obtained preinoculation and at 4, 5, 8, 14, and
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21 days postchallenge. Sera from volunteers challenged with Hawaii virus and
sera from a natural SMV outbreak (15) were also tested.
Specimens from two natural gastroenteritis outbreaks that were originally
diagnosed as NV by human reagent-based ELISA or radioimmunoassay antigen
and antibody tests were also examined. The first outbreak (group I) was clam
associated and occurred in Hawaii in 1983 (1a). The second outbreak (groups IIa
and IIb) of gastroenteritis occurred in Erie County, N.Y., in 1986 (8). Two
distinct components of the second outbreak were involved, which occurred ap-
proximately 2 weeks apart. The first one, group IIa, involved persons who had
eaten at a particular restaurant. The other, group IIb, involved persons attending
a graduation party.
Normal human sera were obtained from a group of adult donors at the
University of Massachusetts Medical Center hospital blood bank and from chil-
dren admitted to the hospital for reasons other than gastroenteritis. All sera were
stored at #220°C.
IgM capture antibody ELISA. Polyvinyl microtiter plates (Dynatech Labora-
tories, Inc., Chantilly, Va.) were coated with unlabeled rabbit anti-human IgM
(Fc5m) (Accurate Chemical, Westbury, N.Y.) at 0.25 mg/50 ml of 0.1 M phos-
phate-buffered saline (PBS) per well. The plates were incubated at 37°C for 2 h,
washed three times (PBS plus 0.15% Tween 20), and blocked overnight at 20 to
22°C with 5.0% bovine serum albumin and 0.25% Bloom 60 gelatin (Sigma
Chemical Co., St. Louis, Mo.) in PBS. The plates were washed three times, and
duplicate twofold serial dilutions of human serum, starting at a 1:25 dilution,
were made in 50% fetal bovine serum (FBS)–50% 0.025 M Tris-HCl buffer (pH
7.2) with 0.015% Tween 20 (50 ml per well) and incubated for 1 h at 37°C. The
plates were washed five times, and 50 ng of rNV in 50 ml of the Tris-HCl-FBS
buffer described above was added to each well of one of the duplicate rows. To
the second row, 50 ml of Tris-HCl-FBS buffer without rNV was added.
After overnight incubation at 20 to 22°C, the plates were washed five times and
a combination of two previously described murine monoclonal antibodies, 1C9
and 1D8 (1:5000 dilution of ascitic fluid), directed against NV (17) was added, in
Tris-HCl-FBS buffer, to all wells and incubated for 1 h at 37°C. We used both
antibodies because we previously found that doing so increased the sensitivity of
the NV detection assay (17). The plates were washed, and peroxidase-labeled
goat anti-mouse IgG (heavy and light chains; Kirkegaard & Perry Laboratories,
Inc., Gaithersburg, Md.) at 1 mg/ml in Tris-HCl-FBS buffer plus 1% normal
rabbit serum was added and incubated for 1 h at 37°C. The plates were washed
five times. Substrate for peroxidase (0.05 ml of o-phenylenediamine–H2O2, Ab-
bott Laboratories, North Chicago, Ill.) was added and left for up to 10 min, and
the reaction was stopped with 0.1 ml of 1 N H2SO4. The A492 of the solution was
measured in a plate reader spectrophotometer (Whittaker Bioproducts, Walk-
ersville, Md.).
The endpoint titer was defined as the highest dilution of serum giving an A492
that was $0.200 above the A492 of the corresponding no-antigen well. This
endpoint was determined by using a value of $3 times the standard deviation of
the A492 obtained with 10 prechallenge sera tested at a 1:25 dilution in no-
antigen wells. To confirm IgM specificity, IgG and IgA were removed from the
group I volunteer sera with Quik-Sep IgM (Isolab Inc., Akron, Ohio) and tested
in the same manner as the whole serum.
IgG antibody ELISA. Alternate rows in polyvinyl microtiter plates were coated
with rNV at 50 ng/50 ml of 0.1 M PBS per well. The plates were incubated at 37°C
for 4 h and washed three times, and all wells were blocked overnight as in the
IgM antibody capture test. The plates were washed three times, and twofold
serial dilutions of human serum, starting at a 1:800 dilution, were made in
Tris-HCl-FBS buffer (50 ml per well) and incubated for 1 h at 37°C. Sera with
titers of ,1:800 were retested at a 1:100 dilution. Dilutions for each serum were
made in both the rNV-coated row and the control row. The plates were washed
four times, and peroxidase-labeled goat anti-human IgG (heavy and light chains;
Kirkegaard & Perry Laboratories, Inc.) at 1 mg/ml in Tris-HCl-FBS buffer was
added and incubated for 1 h at 37°C. Substrate for peroxidase was added as
described for the IgM antibody capture test, and the A492 of the solution was
measured in a plate reader spectrophotometer. The IgG titer was defined as the
highest dilution of serum giving an A492 that was $0.200 higher than that of the
corresponding no-antigen well, based on criteria described for the IgM value.
Sera with acute-phase titers of $1:25,600 were repeat tested.
RT-PCR and sequencing of viruses in stool samples. Stool samples from six
patients in the group II outbreak were analyzed by reverse transcription (RT)-
PCR for HuCVs. Viral nucleic acid was purified from stool as previously de-
scribed (21). Twenty-microliter aliquots of extracted RNA were amplified by
RT-PCR by using two sets of primers: p110-SR48/50/52 (small, round-structured
virus [SRSV] GI specific) and p110-NI (SRSV GII specific) followed by slot blot
hybridization with probes specific for HuCV (23). Samples with virus-specific
amplicons were cloned into TA cloning vector pCRII and transformed into
Escherichia coli One Shot cells in accordance with the manufacturer’s (Invitro-
gen, San Diego, Calif.) instructions. Plasmid DNA from positive clones was
purified with Qiagen Maxi columns (Qiagen, Inc., Chatsworth, Calif.). Cloned
DNA was sequenced by the Nucleic Acids Core Laboratory, Baylor College of
Medicine. Sequence information was analyzed by using the facilities of the
Molecular Biology Computational Resource, Information Technology Program
and The Department of Cell Biology, Baylor College of Medicine.
TABLE 1. Summary of detection studies for NV-specific IgM and
for IgG seroconversions in normal sera, NV volunteers,
and natural outbreaks of NV gastroenteritisa
Group IgM1 IgG scb1 IgM1 IgG sc2 IgG sc1 IgM2
Normal sera (n 5 80) 0 NAc NA NA
Volunteers
I (n 5 10) 9 10 0 1
II (n 5 5) 5 5 0 0
Outbreaks
I (n 5 9)d 9 3 6 0
IIa (n 5 16)e 15 13 3 1
IIb (n 5 8) 4 8 0 4
a See Tables 2 to 6 for detailed analyses.
b sc, seroconversion.
c NA, not applicable.
d Acute-phase sera were collected late (see Table 4).
e Viruses from selected stools were shown to be GI viruses. Those in group IIa
were most closely related to virus MDV1, and those in group IIb were most
closely related to virus V Wal/90/UK (see Results).
TABLE 2. Detection of IgG and IgM responses to NVa





Reciprocal of serum dilution
IgG IgM
1 Preb 12,800 ,25
5 days 6,400 ,25
6 wk 102,400 800
2 Pre 102,400 ,25
9 days 204,800 6,400
3 wk 409,600 6,400
3a Pre 204,800 ,25
6 wk 819,200 1,600
14 wk 204,800 800
3b Pre 51,200 ,25
3 wk 102,400 3,200
6 wk 409,600 1,600
4 Pre 3,200 ,25
3 wk 25,600 800
5 Pre 3,200 ,25
5 days 6,400 ,25
22 wk 25,600 ,25
6 Pre 1,600 ,25
4 wk 204,800 6,400
7 wk 204,800 1,600
7 Pre 12,800 ,25
3 wk 819,200 800
7 wk 409,600 100
8 Pre 1,600 ,25
7 wk 51,200 3,200
18 wk 25,600 3,200
9 Pre 6,400 ,25
5 days 6,400 ,25
6 wk 102,400 3,200
a Samples were from volunteers in studies done in 1970 to 1976. Volunteer 3a
in 1972 was rechallenged in 1976 (volunteer 3b).
b Pre, preinoculation.
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RESULTS
A summary of the results of the studies detailed in Tables 2
to 6 is given in Table 1. No group I or II volunteers demon-
strated detectable IgM in their prechallenge sera (Tables 2 and
3). In group I (Table 2), NV-specific IgM antibodies were
detected in all but one volunteer after virus inoculation. Vol-
unteer 3a, 3b, who was challenged on two occasions (4 years
apart), showed no significant difference in serologic response
to the two challenges. All of these volunteers demonstrated
IgG seroconversion to NV. In group II (Table 3), all volunteers
were IgM negative for up to 5 days after infection and all
became IgM positive by 8 days and were still positive by 21 days
postinoculation (Table 3). In an IgG ELISA to rNV, all of the
volunteers in groups I and II showed fourfold or greater rises
in IgG titer (Tables 2 and 3). Removal of IgG and IgA (by use
of Quik-Sep IgM) in sera from subjects in volunteer group I
did not change the outcome of the test for IgM (data not
shown).
Acute-phase sera from the patients in outbreak group I were
collected 5 to 8 days after the onset of illness. Convalescent-
phase sera were collected 3 to 6 weeks postillness. All nine
patients in outbreak group I had high IgM antibody titers in
both acute- and convalescent-phase sera (Table 4). Four pa-
tients showed fourfold rises in IgM levels. All nine patients had
high titers of IgG antibody to rNV, and three had fourfold or
greater rises in IgG antibody titer. Two patients had rises in
both IgG and IgM antibody titers (Table 4).
Outbreak group II components a and b consisted of 24
patients, 16 in component a and 8 in component b, which
occurred approximately 2 weeks later (Table 5). From patients
in group IIa, acute-phase sera were obtained between 5 and 8
days postexposure and convalescent-phase sera were obtained
3 weeks postexposure. From patients in group IIb, acute-phase
sera were obtained 4 days after a point source exposure and
convalescent-phase sera were obtained 2 weeks postexposure.
Six patients, all of whom were in group IIa, had IgM in their
acute-phase sera. A total of 19 had NV-specific IgM in their
convalescent-phase sera.
Stool samples from six patients involved in the group IIa and
-b outbreak were positive by RT-PCR and by hybridization to
HuCV genogroup 1-specific primers and probes. Five positive
samples were cloned and sequenced. All of the sequences
obtained were related, but not identical, to that of NV (Fig. 1).
The viral sequences from outbreak group IIa stools (those
from patients 1, 4, and 9 in Table 5) were very similar to each
other, with that from patient 9 differing from those from pa-
tients 1 and 4 by one nucleotide. The portions sequenced had
94 to 96% nucleotide sequence identity with an SRSV, V Ward
1/90, from the United Kingdom (28) (accession no. Z29479)
and 70 to 72% nucleotide sequence identity with NV (Fig. 1).
The viral sequences from outbreak group IIb stools (patients
5 and 6 in Table 5) were identical. The portions sequenced had
98% nucleotide identity with a Maryland calicivirus, MDV1
(25) (accession no. U07612) and 77% nucleotide identity with
NV (Fig. 1).
Three serum pairs from volunteers challenged with Hawaii
TABLE 3. Detection of volunteer group II IgG and IgM





Reciprocal of serum dilution
IgG IgM
1 Preb 51,200 ,25
4 days 25,600 ,25
5 days 25,600 ,25
8 days 12,800 1,600
2 wk 102,400 12,800
3 wk 204,800 1,600
2 Pre 3,200 ,25
4 days 3,200 ,25
5 days 3,200 ,25
8 days 204,800 1,600
2 wk 204,800 3,200
3 wk 409,600 3,200
3 Pre 1,600 ,25
4 days 800 ,25
5 days 1,600 ,25
8 days 25,600 3,200
2 wk 51,200 3,200
3 wk 102,400 800
4 Pre 3,200 ,25
4 days 6,400 ,25
5 days 6,400 ,25
8 days 12,800 400
2 wk 409,600 3,200
3 wk 409,600 1,600
5 Pre 1,600 ,25
4 days 800 ,25
5 days 3,200 ,25
8 days 6,400 25
2 wk 51,200 400
3 wk 102,400 800
a Samples were from volunteers in a study done during 1995.
b Pre, preinoculation.
TABLE 4. Detection of IgG and IgM responses to NVa





Reciprocal of serum dilution
IgG IgM
1 7 days 51,200 800
3 wk 102,400 3,200
2 7 days 409,600 1,600
3 wk 409,600 800
3 8 days 51,200 6,400
3 wk 204,800 25,600
4 7 days 51,200 3,200
3 wk 102,400 25,600
5 6 days 25,600 1,600
4 wk 3,276,800 6,400
6 5 days 819,200 3,200
5 wk 819,200 3,200
7 7 days 51,200 6,400
6 wk 51,200 6,400
8 7 days 51,200 12,800
6 wk 51,200 6,400
9 6 days 25,600 3,200
3 wk 3,276,800 3,200
a Samples were from patients involved in a clam-associated outbreak of NV
gastroenteritis in Hawaii in 1983. Sera were collected at the noted intervals
postonset of illness, in contrast to those in Tables 2 and 3.
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virus and four serum pairs obtained from patients involved in
an SMV outbreak were tested for NV-specific IgM. Both
acute- and convalescent-phase samples of all seven serum pairs
were NV IgM negative. However, they did cross-react in the
rNV IgG assay (data not shown). Eighty sera from normal
individuals ranging from 1 to 59 years of age were also tested.
Eighty-five percent of the adults aged 18 to 29 were positive for
NV-specific IgG antibodies, and all of those aged 30 and over
were positive. None of the sera from normal persons were IgM
positive at a 1:25 dilution (Table 6).
DISCUSSION
Previous reports have been inconclusive about whether IgM
antibodies to NV are present in the preinoculation sera of
volunteers in human challenge studies. Two studies showed
that all preinoculation sera were IgM antibody negative (7, 11),
whereas another study found that 40% of preinoculation sera
were NV IgM positive at a serum dilution of 1:20 and 21%
were positive at a 1:40 serum dilution (31). An additional study
found that 10% of preinoculation sera were positive for IgM
antibodies to NV (5). In the two volunteer groups that we
examined, no NV-reactive IgM was detected in preinoculation
sera at a dilution of 1:25. This included both preinoculation
serum samples collected from one volunteer who was chal-
lenged on two occasions 4 years apart. Furthermore, of the 80
sera from blood donors and asymptomatic children tested,
none had detectable IgM antibody to NV at a 1:25 dilution.
Based on our studies, it appears that NV-reactive IgM is
present only after recent exposure to NV or NV-like viruses
and that the test is specific for HuCV GI viruses. One expla-
nation for the two reported studies that showed IgM in prein-
oculation sera is that different assay methods were used. Our
method is the first to use both rNV antigen and anti-NV
monoclonal antibodies to detect NV-reactive IgM in an IgM
capture format.
The time when IgM antibodies to NV can first be detected is
important in identifying outbreaks. In one volunteer study, 2 of
14 volunteers seroconverted as early as 9 days after inoculation
with 8FIIa NV. Six other volunteers were negative 11 days
after inoculation. However, all eventually became positive
(11). No sera were collected from our volunteers in group I
between 5 and 9 days postinoculation. The one volunteer from
whom we collected serum at 9 days postinoculation was IgM
positive. In group II, all five volunteers were negative at 5 days
postinoculation and all were IgM antibody positive by day 8.
Sera were not available from days 6 and 7. It has been shown
that on rechallenge, previously ill volunteers produced IgM
antibody to NV (5). We confirmed this finding by using the
rNV IgM antibody capture format on sera from the one vol-
unteer in group I who had been challenged twice. The time for
development of NV-reactive IgM in the two outbreak groups
TABLE 5. Detection of IgG and IgM responses to NVa





Reciprocal of serum dilution
IgG IgM
IIa
1b 5–8 days 25,600 ,25
3 wk 204,800 3,200
2 5–8 days 12,800 800
3 wk 204,000 800
3 5–8 days 12,800 ,25
3 wk 204,800 6,400
4b 5–8 days 51,200 6,400
3 wk 409,600 6,400
5 5–8 days 6,400 25
3 wk 51,200 800
6 5–8 days 12,800 ,25
3 wk 25,600 25
7 5–8 days 6,400 ,25
3 wk 51,200 ,25
8 5–8 days 102,400 3,200
3 wk 409,600 6,400
9b 5–8 days 25,600 800
3 wk 409,600 3,200
10 5–8 days 25,600 ,25
3 wk 409,600 3,200
11 5–8 days 12,800 ,25
3 wk 102,400 25
12 5–8 days 25,600 ,25
3 wk 51,200 800
13 5–8 days 1,600 ,25
3 wk 102,400 3,200
14 5–8 days 51,200 3,200
3 wk 1,638,400 3,200
15 5–8 days 6,400 ,25
3 wk 102,400 25
16 5–8 days 25,600 ,25
3 wk 51,200 25
IIb
1 4 days 12,800 ,25
2 wk 204,800 800
2 4 days 12,800 ,25
2 wk 51,200 ,25
3 4 days 6,400 ,25
2 wk 51,200 400
4 4 days 6,400 ,25
2 wk 25,600 50
5b 4 days 6,400 ,25
2 wk 51,200 800
6b 4 days 25,600 ,25
2 wk 102,400 ,25
7 4 days 3,200 ,25
2 wk 51,200 ,25
8 4 days 12,800 ,25
2 wk 51,200 ,25
a Samples were from patients involved in two outbreaks of gastroenteritis in
Erie County, N.Y., in 1986 that were reported to be due to NV (8). Sera were col-
lected at the noted intervals postexposure to the virus, in contrast to those in Tables
2 and 3.
b The virus in this patient’s stool sample was analyzed for genogroup (see Fig. 1).
TABLE 6. Prevalence of NV-specific IgG and IgM in





Reciprocal of serum dilution
IgG IgM
,100 $100 ,25 $25
1–4 20 15 5 20 0
5–17 20 7 13 20 0
18–29 20 3 17 20 0
30–59 20 0 20 20 0
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was similar to that found in our volunteers and to that found in
another outbreak study (7).
All patients in outbreak group I were positive for NV-reac-
tive IgM. There was NV-reactive IgM in 15 of 16 patients in
group IIa and in 4 of 8 in group IIb. The difference between the
rates of detection may be due to the two different viruses that
were involved, as shown by viral sequencing. Sequence analysis
showed that neither of the viruses involved was identical to NV
but that both were closer to other described GI viruses, which
was not apparent when the outbreak was originally described
in 1986 (8). Thus, the developed IgM method was able to
detect different GI strains of viruses and was not limited to
detection of antibody to the 8FIIa strain.
The IgM antibody capture test we used did not react with
paired sera from volunteers infected with Hawaii virus, sera
from patients infected with SMV (both viruses are classified as
GII), or normal human sera, showing the specificity of this test
for HuCV GI viruses. However, sera obtained from these
Hawaii virus volunteers and SMV patients did show increases
in the titer of IgG antibody to rNV. A solid-phase immune
electron microscopy study also found that IgM antibodies ap-
peared to be more virus strain specific than IgG antibodies
(26).
Our NV IgM antibody capture enzyme immunoassay is suit-
able for use in the detection of recent NV and other HuCV GI
infections and should be especially useful when appropriate
acute- and convalescent-phase paired sera are not available or
when fecal samples are not collected during the period of
detectable virus shedding. NV is the prototype HuCV, and the
results obtained with this virus and the NV-related viruses we
tested serve as models for other HuCVs.
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